AbbVie gets FDA nod for Orilissa
The Food and Drug Administration has approved AbbVie’s endometriosis pain treatment Orilissa (elagolix). Developed in collaboration with Neurocrine Biosciences, Orilissa is the first and only oral gonadotropin-releasing hormone antagonist specifically developed for women with moderate to severe endometriosis pain, AbbVie said.
"Orilissa represents a significant advancement for women with endometriosis and physicians who need more options for the medical management of this disease," said AbbVie executive vice president research and development, and chief scientific officer Michael Severino, M.D."The approval of Orilissa demonstrates AbbVie's continued commitment to address serious diseases and unmet needs."
The Dept. of Health and Human Services estimates that endometriosis affects roughly 1-in-10 women of reproductive age and can be associated with pain symptoms that can be debilitating.
“Together with AbbVie, we are proud to offer a treatment option for the many women suffering from pain associated with endometriosis,” said Neurocrine Biosciences CEO Kevin Gorman, Ph.D. “Neurocrine discovered Orilissa nearly 20 years ago and through our partnership with AbbVie, the approval of Orilissa reflects our joint commitment to develop therapies for difficult to manage conditions in underserved patient populations.”
"Orilissa represents a significant advancement for women with endometriosis and physicians who need more options for the medical management of this disease," said AbbVie executive vice president research and development, and chief scientific officer Michael Severino, M.D."The approval of Orilissa demonstrates AbbVie's continued commitment to address serious diseases and unmet needs."
The Dept. of Health and Human Services estimates that endometriosis affects roughly 1-in-10 women of reproductive age and can be associated with pain symptoms that can be debilitating.
“Together with AbbVie, we are proud to offer a treatment option for the many women suffering from pain associated with endometriosis,” said Neurocrine Biosciences CEO Kevin Gorman, Ph.D. “Neurocrine discovered Orilissa nearly 20 years ago and through our partnership with AbbVie, the approval of Orilissa reflects our joint commitment to develop therapies for difficult to manage conditions in underserved patient populations.”